Medtronic maintains strong buy rating

Medtronic was maintained at a strong buy rating by JMP Securities analyst Erin Seidemann due largely to Medtronic's lower tax rate of 26% versus the previously expected 28%. Uncertainty remains as to whether Medtronic will be able to launch its Endeavor stent in the United States. JMP is confident, however, that Medtronic can generate 15% earnings-per-share growth regardless of its clinical trial outcome, which will be announced on Oct. 17. JMP raised its earnings-per-share target for the second quarter of fiscal year 2006 to $0.55 from $0.51, with $0.03 from tax.

Shares of the Minneapolis-based biotechnology company were up $1.92, or 3.63%, at $54.79 on volume of 10,023,900 shares versus the three-month running average of 3,521,960 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.